Dr. Thomas Frischmuth at JP Morgan Health 2026 Conference
We are pleased to announce that Dr. Thomas Frischmuth will attending the JP Morgan Health 2026 Conference to present integrated oligonucleotide drug delivery solutions.
Our focus: Combining baseclick’s targeted drug delivery technology with metabion’s world-class oligonucleotide production to help biopharma teams accelerate the development journey from idea to drug product. This collaboration reflects our joint value proposition:
Technology + Production Excellence = Seamless Integration.
Session Highlights
Integrated Platform: baseclick’s sugar-ligand cell-targeting technology pairs with metabion’s custom oligo synthesis to deliver a single, IP-backed support from research to clinical grade manufacturing.
From RUO to GMP material: Practical routes to scale with robust quality systems, reliable QC, and logistics that minimize handoffs and risk.
Faster Development: From concept development to targeted drug delivery – ,“seamless integration”
Customer Outcomes: Efficiency gains and time-to-market benefits when adopting the integrated baseclick – metabion model.
Arrange a Meeting
To schedule a meeting with Dr. Thomas Frischmuth during the conference, please email:
t.frischmuth@baseclick.eu
We recommend booking in advance to secure your slot.
